Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination Therapy in Glaucoma or Ocular Hypertension (India)
NCT01216943Phase 3Completed
- Sponsor
- Allergan
- Start
- Nov 2010
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimatoprost, brimonidine and timolol in Glaucoma and ocular hypertension, sponsored by Allergan. Primary endpoint: Change From Baseline in Mean Diurnal Intraocular Pressure at 12 weeks. Started Nov 2010; status: completed.
02
Drugs
bimatoprostbrimonidinetimolol
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT01216943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01216943.